CIK 0001662579 · Non-accelerated filer<br>Smaller reporting company
C4 Therapeutics, Inc.
Sign in to watch- Ticker
- CCCC
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 475617627
- Phone
- (617) 231-0700
- Business address
- 490 ARSENAL WAY, SUITE 120, WATERTOWN, MA, 02472
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-07 | Fisher Stewart Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +94,950 | 94,950 | ||
| 2024-03-07 | Fisher Stewart Chief Scientific Officer | Returned to the company · Stock Option (Right to Buy) | −118,000 | 0 | ||
| 2024-03-07 | Fisher Stewart Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +118,000 | 118,000 | ||
| 2024-03-07 | Schick Kelly Chief People Officer | Returned to the company · Stock Option (Right to Buy) | −92,000 | 0 | ||
| 2024-03-07 | Schick Kelly Chief People Officer | Grant or award · Stock Option (Right to Buy) | +92,000 | 92,000 | ||
| 2024-03-07 | Schick Kelly Chief People Officer | Returned to the company · Stock Option (Right to Buy) | −78,500 | 0 | ||
| 2024-03-07 | Schick Kelly Chief People Officer | Grant or award · Stock Option (Right to Buy) | +78,500 | 78,500 | ||
| 2024-03-07 | Adams Kendra Chief Financial Officer | Returned to the company · Stock Option (Right to Buy) | −45,000 | 0 | ||
| 2024-03-07 | Adams Kendra Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +45,000 | 45,000 | ||
| 2024-03-07 | Siegel Jolie Chief Legal Officer | Returned to the company · Stock Option (Right to Buy) | −84,850 | 0 | ||
| 2024-03-07 | Siegel Jolie Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +84,850 | 84,850 | ||
| 2024-03-07 | Siegel Jolie Chief Legal Officer | Returned to the company · Stock Option (Right to Buy) | −90,000 | 0 | ||
| 2024-03-07 | Siegel Jolie Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +90,000 | 90,000 | ||
| 2024-02-15 | Hirsch Andrew President & CEO | Shares withheld for taxes | −6,560 | $7.90 | $52K | 210,741 |
| 2024-02-14 | Mossler Mark Chief Accounting Officer | Grant or award | +18,290 | 19,790 | ||
| 2024-02-14 | Mossler Mark Chief Accounting Officer | Grant or award · Stock Option (Right to Buy) | +27,430 | 27,430 | ||
| 2024-02-14 | Hirsch Andrew President & CEO | Grant or award | +103,400 | 217,301 | ||
| 2024-02-14 | Hirsch Andrew President & CEO | Grant or award · Stock Option (Right to Buy) | +465,500 | 465,500 | ||
| 2024-02-14 | REYNO LEONARD Chief Medical Officer | Grant or award | +36,700 | 98,000 | ||
| 2024-02-14 | REYNO LEONARD Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +165,300 | 165,300 |
Page 9 of 27 · 525 trades